Company Registry

Lamassu Pharma Inc
Profile last edited on: 2/18/2021

Increase success rate of clinical trial. • Accelerate drug development process by comprehensive planning
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2530 Meridian Parkway Suite 300
Durham, NC 27703
Multiple Locations:   
Congressional District:   04
County:   Durham

Public Profile

Structured around addressing the gap between when a potentially useful new drug moves from post-discovery and animal eficacy to the clinical phase, Lamassu Pharma personnel are using their expertise in early transisitonal research to address bringing potential products to Phase I/II clincal trial far faster and intimely manner. Begining with a novel, small molecule therapy that was developed by leading players at the Mayo Clinic and that has shown profound efficacy completely to mitigate mortality and morbidity associated with severe acute pancreatitis in animal models, the first drug of focus is a novel small molecule therapy for acute pancreatitis. In the US annually, acute pancreatitis is a leading cause of emergency department visits and gastrointestinal admissions with over 330,000 hospital admissions per year having a significant mortality and long term complications. Expediting the process to in-use condition could enable the company's therapeutics to mitigate the mortality and morbidity associated with severe acute pancreatitis, enabling physicians to save the lives of patients afflicted with this disease with better medical outcomes.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2020 2 NIH $1,498,823
Development of a novel lipase inhibitor for the treatment of acute pancreatitis

Key People / Management

  Gabi Hanna -- CEO

  Rabi Hanna -- Co-Founder and CMO

  Gregory Palmer -- Co-Founder, Manager, CSO

SBIR firms in the news

There are no news available.